Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study
Titel:
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study
Auteur:
Cazzaniga, M.E. Airoldi, M. Arcangeli, V. Artale, S. Atzori, F. Ballerio, A. Bianchi, G.V. Blasi, L. Campidoglio, S. Ciccarese, M. Cursano, M.C. Piezzo, M. Fabi, A. Ferrari, L. Ferzi, A. Ficorella, C. Frassoldati, A. Fumagalli, A. Garrone, O. Gebbia, V. Generali, D. La Verde, N. Maur, M. Michelotti, A. Moretti, G. Musolino, A. Palumbo, R. Pistelli, M. Porpiglia, M. Sartori, D. Scavelli, C. Schirone, A. Turletti, A. Valerio, M.R. Vici, P. Zambelli, A. Clivio, L. Torri, V.